Cargando…

Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone

Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Abiri, Onome T., Johnson, Wiltshire C. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558671/
https://www.ncbi.nlm.nih.gov/pubmed/31198563
http://dx.doi.org/10.1186/s40545-019-0173-2
_version_ 1783425672610316288
author Abiri, Onome T.
Johnson, Wiltshire C. N.
author_facet Abiri, Onome T.
Johnson, Wiltshire C. N.
author_sort Abiri, Onome T.
collection PubMed
description Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the risks by taking appropriate preventative actions to help inform therapeutic decisions, promote rational use of medicines, guide risk management and communications is gradually growing but yet to be fully optimized. This study sought to assess the current status of pharmacovigilance in Sierra Leone since it became the 87th member of the World Health Organisation International Drug Monitoring Programme. This study evaluated the pharmacovigilance system in Sierra Leone through a comprehensive and system-based approach that covered the national medicines regulatory authority, health facilities and public health programmes. A descriptive cross-sectional study design was employed. Using a convenience sampling method, 14 respondents from the national medicines regulatory authority, six health facilities and six public health programmes were interviewed. Data were collected using a validated metric instrument: Indicator-Based Pharmacovigilance Assessment Tool. A scoring system was used for the quantification of assessment results with a score greater than 60% indicating that an organization has structural and policy frameworks to collect and collate safety data in a national database and evaluate the risks and benefits by both active and passive approaches. The study findings showed that the national medicines regulatory authority scored 79% and thus met the standard requirements of pharmacovigilance. On the other hand, the health facilities and public health programmes scored less than 60% indicating the need to fully operationalise pharmacovigilance frameworks at these levels. The study further demonstrated that the national medicine regulatory authority which hosts the national pharmacovigilance centre had functional pharmacovigilance structures and processes with potential to providing leadership in the implementation of pharmacovigilance in Sierra Leone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40545-019-0173-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6558671
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65586712019-06-13 Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone Abiri, Onome T. Johnson, Wiltshire C. N. J Pharm Policy Pract Research Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the risks by taking appropriate preventative actions to help inform therapeutic decisions, promote rational use of medicines, guide risk management and communications is gradually growing but yet to be fully optimized. This study sought to assess the current status of pharmacovigilance in Sierra Leone since it became the 87th member of the World Health Organisation International Drug Monitoring Programme. This study evaluated the pharmacovigilance system in Sierra Leone through a comprehensive and system-based approach that covered the national medicines regulatory authority, health facilities and public health programmes. A descriptive cross-sectional study design was employed. Using a convenience sampling method, 14 respondents from the national medicines regulatory authority, six health facilities and six public health programmes were interviewed. Data were collected using a validated metric instrument: Indicator-Based Pharmacovigilance Assessment Tool. A scoring system was used for the quantification of assessment results with a score greater than 60% indicating that an organization has structural and policy frameworks to collect and collate safety data in a national database and evaluate the risks and benefits by both active and passive approaches. The study findings showed that the national medicines regulatory authority scored 79% and thus met the standard requirements of pharmacovigilance. On the other hand, the health facilities and public health programmes scored less than 60% indicating the need to fully operationalise pharmacovigilance frameworks at these levels. The study further demonstrated that the national medicine regulatory authority which hosts the national pharmacovigilance centre had functional pharmacovigilance structures and processes with potential to providing leadership in the implementation of pharmacovigilance in Sierra Leone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40545-019-0173-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-11 /pmc/articles/PMC6558671/ /pubmed/31198563 http://dx.doi.org/10.1186/s40545-019-0173-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Abiri, Onome T.
Johnson, Wiltshire C. N.
Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_full Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_fullStr Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_full_unstemmed Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_short Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_sort pharmacovigilance systems in resource-limited settings: an evaluative case study of sierra leone
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558671/
https://www.ncbi.nlm.nih.gov/pubmed/31198563
http://dx.doi.org/10.1186/s40545-019-0173-2
work_keys_str_mv AT abirionomet pharmacovigilancesystemsinresourcelimitedsettingsanevaluativecasestudyofsierraleone
AT johnsonwiltshirecn pharmacovigilancesystemsinresourcelimitedsettingsanevaluativecasestudyofsierraleone